Get started
Author

Tiffany T. Khong

Observed names: Khong, Tiffany, T Khong, T. Khong, Tiffany Khong, Tiffany Tee Fern Khong
Observed institutions: The University of Melbourne, Flinders University, Austin Hospital, The Alfred Hospital, St Vincent's Hospital Melbourne, Alfred Health, University of Bari Aldo Moro, Monash University
ORCID: 0000-0002-9376-4223
Observed ORCID: 0000-0002-9376-4223
OpenAlex ID: A5029778692
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
2014 · Sridurga Mithraprabhu, Anna Kalff, et al. · Epigenetics · 175
PDF
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
2021 · Simon J. Hogg, Olga Motorna, et al. · Molecular Cell · 169
PDF
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
2016 · Jia-Nan Gong, Tiffany Khong, et al. · Blood · 150
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma
2016 · S Mithraprabhu, T Khong, et al. · Leukemia · 109
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells
2011 · K A Monaghan, T Khong, et al. · Leukemia · 82
Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients
2019 · Sridurga Mithraprabhu, Rachel Morley, et al. · Leukemia · 61
Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma
2011 · Tiffany Khong, Andrew Spencer · Molecular Cancer Therapeutics · 60
Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment
2022 · Antonia Reale, Tiffany Khong, et al. · Journal of Clinical Medicine · 55
PDF
β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma
2017 · Ioanna Savvidou, Tiffany Khong, et al. · Molecular Cancer Therapeutics · 50
The effect of azacitidine on interleukin-6 signaling and nuclear factor- B activation and its in vitro and in vivo activity against multiple myeloma
2008 · T. Khong, J. Sharkey, et al. · Haematologica · 45
PDF
Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
2018 · Sridurga Mithraprabhu, Shreerang Sirdesai, et al. · International Journal of Molecular Sciences · 40
PDF
Histone deacetylase ( HDAC ) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC
2013 · Sridurga Mithraprabhu, Tiffany Khong, et al. · British Journal of Haematology · 39
DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients
2019 · Sridurga Mithraprabhu, Jay Hocking, et al. · Cancers · 27
PDF
Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton
2014 · S Mithraprabhu, T Khong, et al. · Cell Death and Disease · 27
PDF
Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients
2019 · Maoshan Chen, Sridurga Mithraprabhu, et al. · Cancers · 26
PDF
Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis
1999 · Kathy Paizis, Geoffrey Kirkland, et al. · Kidney International · 25
PDF
Human myeloma cell‐ and plasma‐derived extracellular vesicles contribute to functional regulation of stromal cells
2021 · Antonia Reale, Irena Carmichael, et al. · PROTEOMICS · 20
The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
2021 · Nicholas Nikesitch, Patricia Rebeiro, et al. · Cells · 19
PDF
PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells
2006 · Janelle Sharkey, Tiffany Khong, et al. · Blood · 19
PDF
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)
2019 · Anna Kalff, Tiffany Khong, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 18
Deactylase inhibition in myeloproliferative neoplasms
2010 · Sridurga Mithraprabhu, George Grigoriadis, et al. · Investigational New Drugs · 18
PDF
A Study of VEGF and Its Receptors in Two Rat Models of Proteinuria
2004 · John Kanellis, Vicki Levidiotis, et al. · Nephron Physiology · 18
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
2022 · Ioanna Savvidou, Tiffany Khong, et al. · Cancers · 16
PDF
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
2019 · Noemi Horvath, Andrew Spencer, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16
Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma
2021 · Antonia Reale, Tiffany Khong, et al. · Methods in molecular biology · 15
Works count: 150
Citation count: 1,449
H-index: 19
I10-index: 30
Year
Topic
Type